There is now less than a month until the U.S. Food and Drug Administration (FDA) is expected to approve Ocrevus, generic name ocrelizumab, for use as a therapy for multiple sclerosis.
Clinical trials have shown Genentech’s drug to be a promising therapy for relapsing MS and, significantly, the primary progressive form of the disease for which there is no approved treatment.
The FDA is due to make its decision known March 28, which is quite poetic really, in that it is MS Awareness Month.
So, if everything works out, it looks as if Ocrevus, although not a cure, has all the makings of a wonder drug for MS, at least for most people who have the disease. That is because the vast majority of people with MS have the relapsing form, some 85% worldwide are diagnosed with this type..
However, if, like me, you have secondary progressive MS, then it seems Ocrevus will not be available. No claims have been made of Ocrevus having any effectiveness for our form of MS.
All drugs have side effects and this new one is no exception, but it seems that in all studies the most frequent side effects were mild-to-moderate reactions and infections related to the treatment’s injection.
But that is not enough information for me, and it should not be for you. I decided to dig a little deeper.
The UK’s MS Society says that not one of the Phase 3 trials reported any unexpected adverse side effects and in the Phase 2 relapsing remitting trial, serious side effects were rare and were comparable for all groups.
Wait a minute. Serious side effects?
The UK’s MS Trust also says they are rare and adds that opportunistic infections have not been reported in ocrelizumab MS trials.
Furthermore, in his article “Genentech’s Ocrevus: Pioneering The Progressive MS Therapy Landscape”, on Pharmaceutical Online, John Crowley, PhD, of Decision Resources Group, said: “Ocrevus’ safety profile in MS program is very strong, but some question marks remain.”
It looks to me that, overall, the Ocrevus story is a very positive one.
This article, written by me, was first published by Multiple Sclerosis News Today.
50shadesofsun.com is the personal website of Ian Franks, who is Managing Editor (columns division) of BioNews Services. BioNews is owner of 50 disease/disorder-specific news and information websites – including MS News Today. Ian has enjoyed a successful career as a journalist, from reporter to editor, in the print media. During that career he gained a Journalist of the Year award in his native UK. He was diagnosed with MS in 2002 but continued working until mobility problems forced him to retire early in late 2006. He now lives in the south of Spain. Besides MS, Ian is also able to write about both epilepsy and cardiovascular matters from a patient’s perspective and is a keen advocate on mobility and accessibility issues.
4 thoughts on “Ocrevus: Counting Down to Expected FDA Approval”
I think this might be just another example of too much government intervention. Buy on the other hand, we need to have safety measures in place. So it’s a tough call. I too am in progressive stage. I had to stop Tecfidera as my white blood count got too low, so now I am not on anything. Again, because I am in secondary progressive. It is very disconcerting and frustrating.
I have just this minute finished my 2nd half of first infusion at Raigmore Hospital Inverness.
Please keep me up to date on the newest developments on this.
The safety is worth it.. its the way the labeling restricts low income patients (chronically ill generally) from accessing it. Cause lets be real.. FDA approval then how long till patients on medicaid are able to gain access? years.